Evidence review
Tirzepatide Kidney Outcomes Evidence
Kidney outcomes with tirzepatide are studied mainly within the type 2 diabetes programme and through secondary analyses rather than as a dedicated primary endpoint. Reported signals include effects on albuminuria and estimated GFR decline. Because dedicated renal-outcome evidence for tirzepatide is less mature than for some other agents, this page describes the evidence type rather than asserting a treatment claim.
Key takeaways
- Kidney findings come largely from secondary and exploratory analyses, not dedicated renal trials.
- Reported signals involve albuminuria and eGFR slope rather than dialysis or transplant endpoints.
- Weight and glycaemic improvement both independently affect renal markers, complicating attribution.
- Dedicated renal-outcome evidence is more mature for some other agents than for tirzepatide.
- No renal claim is asserted here pending verified primary-endpoint data.
| Evidence type | Secondary and exploratory analyses within diabetes trials |
|---|---|
| Markers reported | Albuminuria, estimated GFR slope |
| Hard endpoints | Not established here |
| Confounding | Weight loss and glycaemic control independently affect renal markers |
| Status | Evidence developing |
Why are albuminuria and eGFR only partial answers?
They are surrogate markers. Albuminuria responds to blood-pressure and glycaemic changes fairly quickly, and eGFR can dip early on effective therapy before stabilising — a pattern that looks alarming but often precedes benefit. What patients care about are hard endpoints: progression to kidney failure, dialysis, transplant, or death. Those require long, dedicated trials.
- Renal findings largely derive from secondary analyses not powered for renal endpoints.
- Weight reduction and improved glycaemic control both independently move renal markers.
- Trial populations often exclude advanced kidney disease, limiting generalisability.
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Renal outcomes and diabetes context and research gaps, organised around the primary question of tirzepatide kidney study. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Renal outcomes | Covered on this page | Primary evidence |
| Diabetes context and research gaps | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with the registered protocol and the peer-reviewed publication |
What are the limits of what this page can tell you?
Every page on this site rests on a specific primary trial record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the registered protocol and the peer-reviewed publication.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide kidney study.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Does tirzepatide protect the kidneys?
This site does not assert a renal-protection claim. Available findings come from secondary analyses using surrogate markers.
What markers have been reported?
Albuminuria and estimated GFR slope, rather than dialysis or transplant endpoints.
Is it safe with reduced kidney function?
That is a prescriber assessment. Dehydration from severe GI effects is the more immediate renal concern noted in labelling.
Why is the evidence weaker here than for other drugs?
Because dedicated renal-outcome trials exist for some other agents and comparable verified tirzepatide data is not yet reflected on this site.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.